![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directl... Elicio Therapeutics, Inc., formerly Angion Biomedica Corp., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer and other diseases. It provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). The Company is also evaluating the use of ELI-004, a universal AMP-modified clinical practice guidelines (CpG) adjuvant to treat or prevent additional diseases. The Company provides anaplastic lymphoma kinase (ALK) program to identify an internal development candidate. The Company conducts assessments for using ELI-004 to induce immune responses targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Show more
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.29 | -6.30434782609 | 4.6 | 4.99 | 4.15 | 28435 | 4.53367404 | CS |
4 | -2.47 | -36.4306784661 | 6.78 | 7.48 | 3.3419 | 73636 | 4.27679365 | CS |
12 | -4.84 | -52.8961748634 | 9.15 | 11.45 | 3.3419 | 52236 | 6.73952768 | CS |
26 | -0.71 | -14.1434262948 | 5.02 | 11.45 | 2.96 | 57697 | 6.32387726 | CS |
52 | -6.2 | -58.9914367269 | 10.51 | 11.45 | 2.96 | 52671 | 6.27157049 | CS |
156 | -9.69 | -69.2142857143 | 14 | 24.39 | 2.96 | 54893 | 7.46123105 | CS |
260 | -9.69 | -69.2142857143 | 14 | 24.39 | 2.96 | 54893 | 7.46123105 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions